In CPP, treatment with GnRH agonist is considered safe, without significant adverse effects, and can be administered based on the progression of puberty and on the age of the child to stop the development of secondary sex characteristics and to preserve final adult height. This evidence concerns the gene GNRH1 and central precocious puberty.